Analysts Are Bullish on Top Healthcare Stocks: Surgery Partners (SGRY), Stryker (SYK)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Surgery Partners (SGRY – Research Report), Stryker (SYK – Research Report) and CervoMed (CRVO – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Surgery Partners (SGRY)
In a report released today, Brian Tanquilut from Jefferies maintained a Buy rating on Surgery Partners, with a price target of $16.25. The company’s shares closed last Thursday at $13.89.
According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of
Currently, the analyst consensus on Surgery Partners is a Strong Buy with an average price target of $20.31, a 46.3% upside from current levels. In a report issued on March 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $33.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Stryker (SYK)
William Blair analyst Steven Lichtman maintained a Buy rating on Stryker today. The company’s shares closed last Thursday at $373.06.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of
Stryker has an analyst consensus of Strong Buy, with a price target consensus of $431.17, which is a 14.3% upside from current levels. In a report issued on February 18, BTIG also maintained a Buy rating on the stock with a $412.00 price target.
CervoMed (CRVO)
In a report released today, Boobalan Pachaiyappan from Roth MKM maintained a Buy rating on CervoMed, with a price target of $19.00. The company’s shares closed last Thursday at $3.86, close to its 52-week low of $1.80.
According to TipRanks.com, Pachaiyappan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CervoMed with a $22.75 average price target, a 459.0% upside from current levels. In a report issued on February 18, JonesTrading also maintained a Buy rating on the stock with a $20.00 price target.
